Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

The role of comorbidity indices in the prognosis of elderly MDS patients

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 21.02.11
Views: 6903

Prof Valeria Santini - University of Florence, Italy

Prof Valeria Santini talks about the results of her research on the use of comorbidity indexes to determine prognosis for elderly myelodysplastic syndrome patients treated with azacitidine. This trial found that elderly patients with comorbidities can be treated successfully with azacitidine without any substantial increase in adverse effects, however, the level of comorbidities did have a negative influence on overall survival. Prof Santini goes on to discuss the key topics that will be covered at the haematological ecancer conference, Rome 18-20th March 2011.

Related videos

follow us

Immuno-oncology advances in cancer treatment e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation